Eli Lilly & Co Surpasses Q2 Expectations with Strong Revenue Growth, Driven by Weight-Loss Drug Sales
Eli Lilly & Co exceeded Wall Street estimates in its second-quarter financial results, driven by strong sales of its weight-loss drug.
One minute to read









